Risk-sharing agreements are growing at a rate of 24%
Pharmaceutical Technology
FEBRUARY 10, 2023
This is not the first treatment to come with a high price tag. An overwhelming 79% of known RSAs are finance-based, ranging in complexity from simple discount schemes to more complex risk-based financial arrangements. million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.
105 
Let's personalize your content